Axsome Therapeutics (NASDAQ:AXSM) Shares Climb 5.9% – Time to Buy?

Posted by George Bondi on Nov 10th, 2026

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report)’s share price rose 5.9% on Tuesday. The company traded as high as $142.84 and last traded at $141.9250. Approximately 584,541 shares were traded during mid-day trading, a decline of 26% from the average daily volume of 789,292 shares. The stock had previously closed at $133.96.

Analysts Set New Price Targets

Several research analysts have issued reports on AXSM shares. Piper Sandler reduced their price objective on Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating on the stock in a report on Monday, October 26th. UBS Group lowered their target price on Axsome Therapeutics from $256.00 to $239.00 and set a “buy” rating for the company in a research note on Tuesday, November 3rd. Zacks Research raised Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Royal Bank Of Canada dropped their target price on Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating for the company in a research report on Tuesday, November 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $267.58.

Get Our Latest Stock Analysis on AXSM

Axsome Therapeutics Stock Up 5.9%

The company has a market cap of $7.46 billion, a P/E ratio of -46.44 and a beta of 0.86. The company has a current ratio of 1.42, a quick ratio of 1.34 and a debt-to-equity ratio of 1.21. The firm’s 50 day moving average price is $176.31 and its 200-day moving average price is $197.60.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.38. Axsome Therapeutics had a negative net margin of 18.18% and a negative return on equity of 198.73%. The business had revenue of $259.69 million during the quarter, compared to the consensus estimate of $249.19 million. During the same period in the previous year, the firm posted ($0.94) earnings per share. Axsome Therapeutics’s revenue for the quarter was up 51.9% compared to the same quarter last year. As a group, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.57 EPS for the current year.

Insider Buying and Selling

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the sale, the chief operating officer owned 10,000 shares in the company, valued at approximately $2,086,500. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Axsome Therapeutics

A number of institutional investors have recently made changes to their positions in AXSM. BlackRock Inc. bought a new stake in Axsome Therapeutics in the second quarter valued at about $759,695,000. ABS Investment Management LLC bought a new position in Axsome Therapeutics during the second quarter worth about $171,339,000. Bank of America Corp DE acquired a new position in shares of Axsome Therapeutics during the 2nd quarter worth about $110,756,000. First Trust Advisors LP grew its position in shares of Axsome Therapeutics by 1,230.2% during the 1st quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock worth $97,606,000 after buying an additional 534,066 shares during the period. Finally, Pictet Asset Management Holding SA grew its position in shares of Axsome Therapeutics by 12.9% during the 3rd quarter. Pictet Asset Management Holding SA now owns 481,524 shares of the company’s stock worth $88,789,000 after buying an additional 54,997 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

(Get Free Report)

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.